AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26279073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24179293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (∼3000 lux, ∼7 Watts/m(2)) + melatonin (5 mg)
Number of subjects: 36
Study 24179293 — intervention group
Group type: COMPARATOR
Intervention: Bright light (∼3000 lux, ∼7 Watts/m(2))
Number of subjects: 36
Study 24179293 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (5 mg)
Number of subjects: 36
Study 24179293 — intervention group
Group type: COMPARATOR
Intervention: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + placebo
Number of subjects: 36
Study 24179293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + melatonin (5 mg)
Number of subjects: 36
Study 20521076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy)
Number of subjects: 2
Study 20521076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (29% of energy)
Number of subjects: 2
Study 20521076 — intervention group
Group type: COMPARATOR
Intervention: Wash-in diet rich in saturated fatty acids
Number of subjects: 2
Study 18805524 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg daily)
Number of subjects: 60
Study 18805524 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg weekly)
Number of subjects: 60
Study 18805524 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 60
Study 16567432 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine-elevated position
Number of subjects: 0
Study 16567432 — intervention group
Group type: COMPARATOR
Intervention: Supine-flat position
Number of subjects: 0
Study 15034228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 68
Study 11439832 — intervention group
Group type: EXPERIMENTAL
Intervention: Visited mothers (n = 108)
Number of subjects: 212
Study 11439832 — intervention group
Group type: COMPARATOR
Intervention: Nonvisited mothers (n = 104)
Number of subjects: 212
Study 9886891 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg three times a day (tid)
Number of subjects: 3132
Study 9886891 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3132
Study 7987364 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 35% intensity
Number of subjects: 9
Study 7987364 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 60% intensity
Number of subjects: 9
Study 7987364 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 75% intensity
Number of subjects: 9
Study 7987364 — intervention group
Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 35% intensity
Number of subjects: 9
Study 7987364 — intervention group
Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 60% intensity
Number of subjects: 9
Study 7987364 — intervention group
Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 75% intensity
Number of subjects: 9
Study 2736696 — intervention group
Group type: EXPERIMENTAL
Intervention: Li Dan Ling treatment group
Number of subjects: 89
Study 2736696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 1098726 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative intermittent calf compression with low-dose heparin
Number of subjects: 84
Study 1098726 — intervention group
Group type: COMPARATOR
Intervention: Peroperative intermittent calf compression without low-dose heparin (control)
Number of subjects: 84
Study 31302353 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training (RehaCom software, 16 sessions)
Number of subjects: 65
Study 31302353 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment alone
Number of subjects: 65
Study 31302353 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Number of subjects: 65
Study 31302353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training in schizophrenia patients
Number of subjects: 65
Study 27050662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear resistance training (NLRT)
Number of subjects: 21
Study 27050662 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study 24431394 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks
Number of subjects: 194
Study 24431394 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 194
Study 24431394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 23290018 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 allele presence
Number of subjects: 99
Study 23290018 — intervention group
Group type: COMPARATOR
Intervention: Proinflammatory and prothrombotic polymorphisms
Number of subjects: 99
Study 21799138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic balance exercises coupled with video game play
Number of subjects: 30
Study 21799138 — intervention group
Group type: COMPARATOR
Intervention: Typical rehabilitation program consisting of strengthening and balance exercises
Number of subjects: 30
Study 19825777 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with functional after-treatment
Number of subjects: 83
Study 19825777 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment by functional bracing
Number of subjects: 83
Study 16891328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide, long needle (23 gauge/0.6 mm diameter, 25 mm)
Number of subjects: 696
Study 16891328 — intervention group
Group type: COMPARATOR
Intervention: Narrow, short needle (25 gauge/0.5 mm diameter, 16 mm)
Number of subjects: 696
Study 16891328 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow, long needle (25 gauge, 25 mm)
Number of subjects: 696
Study 15388005 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene plus MVP chemotherapy (mitomycin, vindesin, and cisplatin)
Number of subjects: 63
Study 15388005 — intervention group
Group type: COMPARATOR
Intervention: Control arm (MVP chemotherapy only)
Number of subjects: 63
Study 15388005 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment arm (previously treated with chemotherapy)
Number of subjects: 63
Study 11399102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (Hyalgan), 20 mg/2 ml once a week for 5 weeks
Number of subjects: 24
Study 11399102 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (Depo‐Medrol, 40 mg/1 ml once a week for 3 weeks)
Number of subjects: 24
Study 9416723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (total dose, 6 x 10(6) kallikrein inactivator units)
Number of subjects: 204
Study 9416723 — intervention group
Group type: COMPARATOR
Intervention: Epsilon-aminocaproic acid (total dose, 270 mg/kg)
Number of subjects: 204
Study 8495761 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with adjunctive leuprolide acetate (LA) therapy
Number of subjects: 0
Study 8495761 — intervention group
Group type: COMPARATOR
Intervention: Superovulation without adjunctive leuprolide acetate (LA) therapy
Number of subjects: 0
Study 8495761 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold P concentrations proposed in other studies
Number of subjects: 0
Study 3122065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 3 times weekly for 1 month
Number of subjects: 25
Study 3122065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 7 times weekly for 1 month
Number of subjects: 25
Study 3122065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 3 times weekly for 1 year
Number of subjects: 25
Study 3122065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 3 times weekly after cessation of long-term drug therapy
Number of subjects: 25
Study 31701861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer and respiratory hygiene education
Number of subjects: 24
Study 31701861 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 29976277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group, n=49)
Number of subjects: 103
Study 29976277 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg once daily (standard treatment group, ST group, n=54)
Number of subjects: 103
Study 29976277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group)
Number of subjects: 103
Study 29976277 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg once daily (standard treatment group, ST group)
Number of subjects: 103
Study 26988432 — intervention group
Group type: COMPARATOR
Intervention: 14% Plai cream
Number of subjects: 75
Study 26988432 — intervention group
Group type: COMPARATOR
Intervention: 7% Plai cream
Number of subjects: 75
Study 26988432 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 75
Study 23846158 — intervention group
Group type: EXPERIMENTAL
Intervention: HCE (exercise group, n = 8)
Number of subjects: 14
Study 23846158 — intervention group
Group type: COMPARATOR
Intervention: HCS (control group, n = 6)
Number of subjects: 14
Study 23846158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 22082345 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Strategies Scale (CSS)
Number of subjects: 751
Study 22082345 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief versions of the CSS
Number of subjects: 751
Study 22082345 — intervention group
Group type: EXPERIMENTAL
Intervention: CSS and brief versions of CSS
Number of subjects: 751
Study 19460131 — intervention group
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation
Number of subjects: 28
Study 19460131 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Number of subjects: 28
Study 17314580 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus sucking (A)
Number of subjects: 66
Study 17314580 — intervention group
Group type: EXPERIMENTAL
Intervention: SS performed by nurses (B)
Number of subjects: 66
Study 17314580 — intervention group
Group type: EXPERIMENTAL
Intervention: SS performed by mothers (C)
Number of subjects: 66
Study 16271099 — intervention group
Group type: EXPERIMENTAL
Intervention: S-303-treated RBCs
Number of subjects: 223
Study 16271099 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 223
Study 12136225 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention (specific, objective information about radiation treatments)
Number of subjects: 152
Study 12136225 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (general information)
Number of subjects: 152
Study 9836030 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized tutorial regarding PCA use (20 min)
Number of subjects: 85
Study 9836030 — intervention group
Group type: COMPARATOR
Intervention: No additional education apart from routine preoperative anaesthetic consultation
Number of subjects: 85
Study 8133537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied all-trans-retinoic acid (RA) 0.372%
Number of subjects: 301
Study 8133537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 2683543 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral blockade with bupivacaine 0.5% (15 ml followed by 5 ml/h)
Number of subjects: 20
Study 2683543 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural blockade with bupivacaine 7 ml 0.5% + morphine 2 mg followed by 5 ml/h + 0.2 mg/h
Number of subjects: 20
Study 2683543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 1137478 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise plus biofeedback training
Number of subjects: 20
Study 1137478 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 20
Study 1137478 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 20
Study 31888788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Children's Asthma Action Plan (CCAAP) instructions
Number of subjects: 173
Study 31888788 — intervention group
Group type: COMPARATOR
Intervention: Usual asthma care
Number of subjects: 173
Study 29785889 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation at 0.5 g/kg feed
Number of subjects: 96
Study 29785889 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation at 1.0 g/kg feed
Number of subjects: 96
Study 29785889 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation at 2.0 g/kg feed
Number of subjects: 96
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo hypoalgesia (green cue)
Number of subjects: 0
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo hyperalgesia (red cue)
Number of subjects: 0
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV mean amplitude (early component)
Number of subjects: 0
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV mean amplitude (late component)
Number of subjects: 0
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time
Number of subjects: 0
Study 28106308 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 2 (no conditioning)
Number of subjects: 0
Study 24119149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU) administered orally every week for 8 weeks
Number of subjects: 53
Study 24119149 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally every week for 8 weeks
Number of subjects: 53
Study 22930072 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatted flaxseed
Number of subjects: 18
Study 22930072 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 18
Study 22930072 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole flaxseed
Number of subjects: 18
Study 22930072 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatted flaxseed and placebo muffins
Number of subjects: 18
Study 22930072 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole flaxseed and defatted flaxseed
Number of subjects: 18
Study 22026529 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine auricular therapy
Number of subjects: 0
Study 22026529 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular therapy (control)
Number of subjects: 0
Study 22026529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (genuine auricular therapy and sham)
Number of subjects: 0
Study 19187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (0.25 + 1 mg, 3 + 6 mg, 16 + 24 mg, 48 + 60 mg, 80 + 104 mg)
Number of subjects: 39
Study 19187286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17519067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 100
Study 17519067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 100
Study 17519067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15382776 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer luting cement (Vitremer)
Number of subjects: 20
Study 15382776 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate luting cement
Number of subjects: 20
Study 16280089 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs and/or SMT in addition to general practitioner advice and paracetamol
Number of subjects: 240
Study 10326923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic wheelchair cushion (upright position)
Number of subjects: 16
Study 10326923 — intervention group
Group type: COMPARATOR
Intervention: Gel cushion (tilted position)
Number of subjects: 16
Study 10326923 — intervention group
Group type: COMPARATOR
Intervention: Dry-flotation cushion (tilted position)
Number of subjects: 16
Study 10326923 — intervention group
Group type: COMPARATOR
Intervention: Gel cushion (upright position)
Number of subjects: 16
Study 10326923 — intervention group
Group type: COMPARATOR
Intervention: Dry-flotation cushion (upright position)
Number of subjects: 16
Study 8566580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracolonic injection of glycerol
Number of subjects: 0
Study 8566580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal injection of glycerol
Number of subjects: 0
Study 8566580 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (administered prior to glycerol injection)
Number of subjects: 0
Study 8566580 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil (control for glycerol injection)
Number of subjects: 0
Study 8566580 — intervention group
Group type: COMPARATOR
Intervention: Octreotide and granisetron (drugs acting on visceral afferent pathways)
Number of subjects: 0
Study 8566580 — intervention group
Group type: COMPARATOR
Intervention: Phloroglucinol (spasmolytic drug)
Number of subjects: 0
Study 2019798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Shah grommet
Number of subjects: 116
Study 2019798 — intervention group
Group type: COMPARATOR
Intervention: Conventional Shah grommet
Number of subjects: 116
Study 7184471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tuberculin jelly (14 patients)
Number of subjects: 21
Study 7184471 — intervention group
Group type: COMPARATOR
Intervention: Yellow petrolatum (7 patients)
Number of subjects: 21
Study 29713891 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 group (T1) - one shade tissues, B1B
Number of subjects: 20
Study 29713891 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 group (T2) - two-shades tissues, A2Dentin and B1Enamel
Number of subjects: 20
Study 29713891 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 3 group (T3) - three shade tissues, A2Dentin, Transparent, and B1Enamel
Number of subjects: 20
Study 29713891 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Group - dental tissues with enamel, dento-enamel junction DEJ, and dentin
Number of subjects: 20
Study 28643207 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of parents with less severe depression (n=19)
Number of subjects: 31
Study 28643207 — intervention group
Group type: COMPARATOR
Intervention: Children of parents with more severe depression (n=12)
Number of subjects: 31
Study 26414696 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-rate exercise (FE)
Number of subjects: 27
Study 26414696 — intervention group
Group type: COMPARATOR
Intervention: Voluntary-rate exercise (VE)
Number of subjects: 27
Study 24378206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 393
Study 24378206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 393
Study 24378206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 22980299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18610
Study 22980299 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18610
Study 20178036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural priming with individualism
Number of subjects: 0
Study 20178036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural priming with collectivism
Number of subjects: 0
Study 20178036 — intervention group
Group type: COMPARATOR
Intervention: Control condition (unfamiliar person)
Number of subjects: 0
Study 17572422 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐estradiol 1 mg plus dydrogesterone 10 mg sequential added (LD‐HT; group A)
Number of subjects: 120
Study 17572422 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone 10 mg from day 15 to 28 (group B)
Number of subjects: 120
Study 16153515 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) examinations performed by trained physicians
Number of subjects: 10000
Study 11845759 — intervention group
Group type: EXPERIMENTAL
Intervention: Washable pants with integral pads
Number of subjects: 72
Study 10217391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 0
Study 10217391 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for reductions in febrile neutropenia
Number of subjects: 0
Study 10217391 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for reductions in neurotoxicity
Number of subjects: 0
Study 10217391 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for reductions in nephrotoxicity
Number of subjects: 0
Study 10217391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (base case analysis)
Number of subjects: 0
Study 8824737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunder Vati
Number of subjects: 82
Study 8824737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8824737 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Ayurvedic formulations
Number of subjects: 82
Study 30686952 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1107 (adult tetanus diphtheria vaccine)
Number of subjects: 253
Study 30686952 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Td vaccine)
Number of subjects: 253
Study 28892121 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 7213
Study 28892121 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users with elevated total cholesterol
Number of subjects: 7213
Study 28892121 — intervention group
Group type: COMPARATOR
Intervention: Non-users with elevated total cholesterol
Number of subjects: 7213
Study 25608632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Axetil (FA) with fentanyl in postoperative controlled intravenous analgesia (PCIA)
Number of subjects: 50
Study 25608632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 23592107 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave + BMCs
Number of subjects: 103
Study 23592107 — intervention group
Group type: COMPARATOR
Intervention: Shock wave + placebo infusion
Number of subjects: 103
Study 23592107 — intervention group
Group type: COMPARATOR
Intervention: Placebo shock wave + BMCs
Number of subjects: 103
Study 22104320 — intervention group
Group type: EXPERIMENTAL
Intervention: ½ cup of pinto beans for 8 weeks (Study 1)
Number of subjects: 86